Goldman Sachs Issues Buy Rating for Hologic, Noting Contributions from Gen-Probe Purchase | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs has placed a Buy rating on Hologic with a six-month price target on its stock of $24, as the Gen-Probe acquisition, completed a week ago, is expected to accelerate top line growth.

Analyst Isaac Ro removed his previous Not Rated designation on the Bedford, Mass.-based company and increased revenue estimates for fiscal-year 2012 to $2.00 billion from an earlier estimate of $1.91 billion, but he lowered the EPS estimate to $1.36 from $1.38.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.